You are here

Company Monitoring Page for Ipsen

latest headlines for company on cafepharma

After Albireo buyout, Ipsen's Bylvay picks up new FDA-approved use

Fierce Pharma

Wed, 06/14/23 - 10:22 am

Tags:

Ipsen, Bylvay, Albireo Pharma, M&A, FDA, liver disease

Biotech M&A is picking back up - here are the latest deals

BioPharma Dive

Tue, 06/13/23 - 11:37 am

Pfizer's fortunes overshadow first-quarter dealmaking

EP Vantage

Wed, 04/12/23 - 10:22 am

Tags:

M&A, Pfizer, Seagen, Sanofi, Provention Bio, AstraZeneca, CinCor, Chiesi, Amryt, Ipsen, Albireo

FDA agrees to give Ipsen's rare disease drug another look as palovarotene saga rumbles on

Fierce Biotech

Sun, 03/19/23 - 01:34 pm

Tags:

Ipsen, FDA, palovarotene, fibrodysplasia ossificans progressiva

Ipsen reports positive data from pancreatic ductal adenocarcinoma trial

Clinical Trials Arena

Mon, 01/23/23 - 10:53 am

Tags:

Ipsen, Onivyde, metastatic pancreatic cancer, pancreatic cancer, clinical trials

Irlab's shares plummet 60% after Ipsen-partnered Parkinson's drug flunks phase 2 trial

Fierce Biotech

Thu, 01/19/23 - 10:03 am

Tags:

Ipsen, IRLAB, clinical trials, Parkinson's Disease, mesdopetam

Biopharma’s bolt-on bonanza is set to continue

EP Vantage

Thu, 01/12/23 - 10:18 am

Tags:

M&A, Amgen, AstraZeneca, Bristol Myers Squibb, GSK, Ipsen, Merck, Pfizer

Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting

BioPharma Dive

Mon, 01/9/23 - 10:43 am

Tags:

JPMHC 2023, M&A, AstraZeneca, CinCor, Ipsen, Albireo, Chiesi Farmaceutici, Amryt Pharma

Ipsen's rare disease candidate rejected after mounting setbacks, delays

Fierce Biotech

Fri, 12/30/22 - 10:48 am

Tags:

Ipsen, FDA, palovarotene

AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure

Fierce Biotech

Wed, 12/14/22 - 10:44 am

Tags:

Exicure, AbbVie, Ipsen, R&D

Go or no go? Mirati heads to the FDA

EP Vantage

Wed, 11/30/22 - 10:34 am

Tags:

FDA, Mirati Therapeutics, Gilead Sciences, Coherus Biosciences, Roche, Biogen, TG Therapeutics, Ipsen, Novartis, BeiGene, Cytokinetics

Halloween adcomm postponed as FDA seeks more Ipsen data on ultra rare disorder drug candidate

Endpoints

Tue, 10/25/22 - 11:09 pm

Tags:

Ipsen, FDA, fibrodysplasia ossificans progressiva

Go or no go? GSK takes its turn with a novel anemia class

EP Vantage

Fri, 09/30/22 - 10:52 am

Tags:

FDA, GSK, Amicus Therapeutics, AstraZeneca, Novartis, Supernus, JNJ, Ipsen, Y-mAbs Therapeutics

Ipsen becomes the latest pharma to expand in Ireland, with a $50M investment in its facility in Dublin suburbs

Endpoints

Mon, 09/26/22 - 11:23 pm

Tags:

Ipsen, Ireland, drug manufacturing

ESMO: It’s early days for Pfizer’s EZH2 inhibitor, but there’s a glimpse of hope for some

Fierce Biotech

Sun, 09/11/22 - 10:58 pm

Tags:

ESMO, Pfizer, Ipsen, EZH2 inhibitors, Epizyme

Trick, or treat? FDA plans Halloween adcomm for Ipsen’s second chance at rare disease drug

Endpoints

Mon, 08/22/22 - 08:10 pm

Tags:

Ipsen, FDA, bone disease, palovarotene

PhIII fail in overall survival measure clouds Ipsen's expansion plans for cancer drug Onivyde

Endpoints

Wed, 08/3/22 - 10:51 am

Tags:

Ipsen, Onivyde, small cell lung cancer, clinical trials

Ipsen jumps into the TCR space, teaming with startup helmed by former Merck KGaA cancer chief

Endpoints

Mon, 08/1/22 - 10:51 am

Tags:

Ipsen, Marengo Therapeutics, TCR immunotherapy

Epizyme SEC filing details its desperate days in free fall before $247M sale to Ipsen

Fierce Pharma

Wed, 07/13/22 - 10:09 am

Tags:

Epizyme, SEC, M&A, Ipsen

Pages

last 30 twitter posts